Dermorphin Dosage Chart - Peptide Dosages

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Dermorphin (5 mg) Dosage Protocol

A potent mu-opioid heptapeptide from frog skin, studied in animal analgesia and pharmacology. It is a laboratory research reagent only — not approved for, and not intended for, human or veterinary administration.

Why Dermorphin draws research interest

These are the directions researchers and the peptide community most often explore Dermorphin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

A natural opioid with a D-amino acid

Almost all animal peptides are built entirely from L-amino acids. Dermorphin is a striking exception: it carries a D-alanine at position 2, which the frog produces by enzymatically flipping an L-alanine after the peptide is made. That single change blocks the enzymes that would normally chew up the peptide, which is a large part of why such a small molecule is so potent at the mu-opioid receptor.

Potent in animals is not the same as safe or usable

In rodent studies dermorphin produces analgesia at fractions of the equivalent morphine amount, and it can act in the brain after peripheral injection. But greater potency at the mu-opioid receptor also means the opioid liabilities — respiratory depression, sedation, dependence — scale with it. Potency in a rat assay is a pharmacology finding, not evidence that the compound is safe to give to a person or an animal.

The one place it shows up in the real world is cheating

Dermorphin gained public notice when it was found being injected into racehorses as an illicit analgesic to mask pain and boost performance. It is a classified doping agent in equine racing, and forensic laboratories have validated urine tests to catch it. That is the honest context for anyone encountering it: a prohibited substance, documented as a warning, not a protocol.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

Mix & measure Dermorphin · 5 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

A frog-skin heptapeptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) that is a highly selective, high-affinity agonist at the mu-opioid receptor. Its unusual D-alanine residue resists breakdown and underlies a potency several times that of morphine in animal antinociception assays.

A laboratory research reagent, not a drug. It is not approved for human or veterinary use, has no established dose, and is prohibited in sport. Its most notable real-world appearance is as an illegally administered analgesic ("nerve blocker") in horse racing, which anti-doping laboratories now test for.

Effects are characterized in animal models: potent antinociception, catalepsy at higher amounts, and dose-dependent respiratory and blood-pressure changes typical of a mu-opioid. There are no controlled human therapeutic trials and no approved indication.

Quickstart Highlights

Dermorphin is a naturally occurring opioid heptapeptide — sequence H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 — first isolated in 1981 from the skin of the South American frog Phyllomedusa sauvagei[1]. It is one of the very few animal peptides to contain a D-amino acid (D-alanine at position 2), an unusual feature that is generated post-translationally by enzymatic conversion of an L-alanine encoded in the gene[2]. That single D-residue is what makes the peptide resistant to peptidases and gives it its remarkable potency at the mu-opioid receptor.

This page is an educational reference on what dermorphin is, how it behaves in the research literature, and how a research vial is reconstituted. It is not medical advice and not a protocol to administer the compound to any organism. Dermorphin is not approved by the FDA or any regulator for human or veterinary use; the only human-relevant context in which it appears is as a prohibited doping agent, and its use in racehorses is an illegal abuse, documented here as a warning rather than a practice to follow[6].

A mu-opioid receptor agonist heptapeptide from Phyllomedusa frog skin[1]. In rodents it is a far more potent analgesic than morphine, and it can cross the blood-brain barrier to act centrally[4].

2 mL bacteriostatic water per 5 mg vial → 2.5 mg/mL. This is a lab-handling reference only; the site provides no dose for administration to humans or animals.

Not FDA-approved for any use. Classified as a doping agent in equine racing and prohibited in sport[6]. There is no legitimate self-administration context.

Animal pharmacology only. The analgesic, cataleptic, respiratory and cardiovascular data are from rodents[3][5]; the dermorphin family has been studied in primates including humans only in early pharmacology, not as an approved medicine[4].

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Teduglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Teduglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

02Davunetide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Davunetide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

03VK2735 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. VK2735 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

04GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

05P21 — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. P21 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗

Research context

Read sources and limitations before applying a claim.

What We Still Do Not Know: The Real Evidence Gaps

An honest inventory of open questions is more useful than a list of hopeful claims, so here is where the actual gaps lie — the places where a researcher can say precisely what is missing. The overarching problem is that Sermorelin’s own high-quality clinical evidence base is concentrated in the pediatric-diagnostic and pediatric-deficiency setting for which it was approved, and much of the modern enthusiasm rests on extrapolation from that setting, from adjacent stabilized analogs, or from mechanism alone.3 The table below separates what is reasonably established from what remains hypothesis. Pituitary stimulation Sermorelin reliably provokes endogenous GH release via GHRHR3 Durability and clinical meaning of chronic stimulation in non-deficient adults Diagnosis of GHD Validated as a provocative test (incl. GHRH-arginine)9 Whether/how to restore standardized GHRH-based testing to practice7 Somatopause / aging GH/IGF-1 decline with age is real and measurable8 Whether restoring the axis helps or harms over years8 Cognition A GHRH analog (tesamorelin) improved executive function in a trial5 Whether Sermorelin specifically reproduces this effect5 Body composition Stabilized GHRH analog reduces visceral fat in a defined disease10 Whether Sermorelin changes body composition meaningfully in healthy adults Long-term safety Short-term tolerability appears acceptable in studied settings4 Multi-year safety, especially any oncologic signal from raised IGF-1 Several of these gaps deserve emphasis because they are routinely papered over. The healthy-adult body-composition question is largely unstudied for Sermorelin itself; the visceral-fat data belong to tesamorelin in a specific disease population, and importing them is precisely the analog-substitution error.10 The long-term safety question is not hypothetical hand-wringing: IGF-1 is a mitogen, epidemiology links higher IGF-1 to certain cancer risks, and any intervention that chronically raises IGF-1 in older adults carries a theoretical oncologic concern that short trials cannot exclude. That the Baker trial kept IGF-1 “within the physiological range” is reassuring for that protocol but does not settle the matter for uncontrolled, indefinite off-label use.5 And the durability question follows directly from the pharmacology: a compound cleared in minutes, dosed to nudge nightly pulses, has no established multi-year outcome data in the wellness populations now using it. It is worth being blunt about the shape of the literature itself, because the type of evidence matters as much as its quantity. The frequently cited case for adult Sermorelin rests substantially on a two-page 2006 commentary framing it as “a better approach” to adult-onset GH insufficiency — a thoughtful argument from mechanism and clinical reasoning, but explicitly a hypothesis-generating perspective piece, not a randomized controlled trial reporting hard endpoints.4 There is, to date, no large, modern, placebo-controlled outcome trial of Sermorelin itself in healthy or aging adults that measures function, body composition, cognition, or safety over years and clears contemporary methodological standards. What exists instead is a scaffold assembled from three weaker supports: the robust but pediatric-diagnostic dataset for which the drug was approved,3 the well-run trials of other GHRH analogs such as tesamorelin,510 and the biologically reasonable but unproven inference that the same axis stimulation will translate into benefit. Recognizing that structure is not cynicism; it is simply reading the evidence at the level of rigor it actually occupies rather than the level its marketing implies. The methodological bottom line is that Sermorelin’s evidence architecture was built to answer a pediatric-diagnostic question and answered it well. It was not built to answer the adult anti-aging, body-composition, or cognition questions now asked of it, and those answers cannot be manufactured by borrowing from tesamorelin or from mechanism. For a grounded look at what the primary literature does and does not say about the compound’s core action, the site’s overview of what research says about Sermorelin’s role in stimulating natural growth hormone stays close to the demonstrated pharmacology.

Source: dosagepeptide.com ↗

Research Models and How Lipogenesis Is Actually Measured

Understanding how AOD-9604 has been studied clarifies both what the data can support and what a real antilipogenic investigation would require. The methodology falls into three tiers, and only the first touches lipogenesis directly. Ex vivo and in vitro fat-tissue work. The foundational studies examined lipolysis and lipogenesis in adipose tissue and isolated fat cells, measuring free-fatty-acid and glycerol release, fat oxidation, and — critically — the activity of lipogenic enzymes such as acetyl-CoA carboxylase.23 Enzyme-activity assays of this kind are the appropriate tool for an antilipogenic claim, and they are the source of the strongest evidence that a C-terminal domain peptide can suppress fat synthesis. A more complete modern program would add radiolabeled- or deuterium-tracer incorporation into fatty acids to quantify DNL flux, plus expression of ACC, FASN, SREBP-1c, and ChREBP under the peptide. Rodent models. The most methodologically informative animal work is the β3-AR knockout study, a clean genetic approach that isolated the receptor’s contribution by comparing knockout and wild-type mice under identical treatment.4 Obese Zucker rats and ob/ob mice provided body-weight, fat-mass, and substrate-oxidation readouts.15 These are genetically obese metabolic models, well suited to whole-body fat-balance questions but blunt instruments for isolating lipogenesis from lipolysis, since net fat change reflects both. Human trials. The clinical methodology was appropriate for an obesity drug — randomized, double-blind, placebo-controlled designs with weight and body-composition endpoints, plus dedicated safety and pharmacokinetic studies.610 A safety and tolerability study specifically characterized the peptide in humans.6 But none of these used lipogenesis endpoints. To answer this article’s question in humans would require a purpose-built study: stable-isotope measurement of de novo lipogenesis, adipose and hepatic lipogenic-gene expression, and controlled dosing — work that has never been done for AOD-9604. The methodological bottom line is that the antilipogenic evidence is strongest exactly where it is least generalizable (isolated rodent fat-tissue enzyme assays) and absent exactly where it would matter most (human DNL flux). Until that gap is filled, any statement that AOD-9604 “reduces lipogenesis in humans” is hypothesis, not finding. Terminology used across this literature — lipogenesis, lipolysis, DNL, ACC, FASN — is defined for reference in the site’s peptide and metabolism glossary.

Source: dosagepeptide.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗

Dosage reference

MGF (5mg Vial) Dosage Protocol

Mechano Growth Factor (IGF-1 splice variant) studied for muscle repair — research/educational dosing reference.

Source: dosagepeptide.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Dermorphin (5 mg) Dosage Protocol

Why Dermorphin draws research interest

A natural opioid with a D-amino acid

Potent in animals is not the same as safe or usable

The one place it shows up in the real world is cheating

Mix & measure Dermorphin · 5 mg

Quickstart Highlights

Related questions

What We Still Do Not Know: The Real Evidence Gaps

Research Models and How Lipogenesis Is Actually Measured

How to convert mcg to mg (and back)

MGF (5mg Vial) Dosage Protocol

Peptide Therapy Guide Editorial Team

VIP Peptide Dosage Chart - Peptide Dosages

VK2735 Dosage Chart - Peptide Dosages

Triptorelin Acetate Dosage Protocol - Peptide Dosages

Vilon (20mg Vial) Dosage Chart - Peptide Dosages